series-a
Stage
About
Shennon Bio develops precision immunotherapies for solid tumors using a proprietary single-cell functional screening platform combined with computational engineering to identify and optimize next-generation T-cell engagers targeting cancer.
Explore Shennon Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.